Search

Displaying results 2141 - 2150 of 3178 in total
  1. Drug

    Acetylcysteine

    go.drugbank.com/drugs/DB06151
    ApprovedInvestigational

    Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. Ac...

    Synonyms: N-AC, N-acetylcysteineMixtures: AMINOSTERIL N-HEPA 500 ML SOLUSYON, N-ACETILCISTEÍNA MAS GUAYACOLATO DE GLICERILO
  2. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impair...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 re...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Garenoxacin

    go.drugbank.com/drugs/DB06160
    Experimental

    Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  5. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also be...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  6. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

    Categories: P-glycoprotein inhibitors
  7. Drug

    Tolperisone

    go.drugbank.com/drugs/DB06264
    Investigational

    Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentr...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  9. Drug

    Amisulpride

    go.drugbank.com/drugs/DB06288
    ApprovedInvestigational

    Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and ...

    Synonyms: 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamideCategories: P-glycoprotein substrates
  10. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. It re...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates